MALVERN, Pa., Dec. 10, 2015 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of senior executives as it builds its team to support the commercialization of ZTlido™.
ZTlido™ (lidocaine patch 1.8%) is a next-generation patch being developed for the treatment of postherpetic neuralgia, or after-shingles pain. SCILEX's new drug application for ZTlido™ was accepted by the FDA in September and has a PDUFA date in the second quarter of 2016.
The new hires include Mr. Dean Ferrigno as Vice President of Finance and Mr. Kip Vought as Vice President of Development.
"Our ability to secure this caliber of industry expertise places us in an excellent position as we determine the commercialization potential of several pain treatment products beyond our initial product, ZTlido™," said Anthony Mack, Chief Executive Officer of SCILEX.
The new appointments will be followed by other senior hires in sales and marketing to ensure SCILEX has the expertise to continue expanding its pain product pipeline and successfully commercialize its products.
Mr. Vought has more than 20 years of industry regulatory experience in U.S. and international markets. For the past several years, he has been consulting to SCILEX on regulatory affairs and strategic development. Mr. Vought has held senior roles at Regulus Pharmaceutical Consulting, Clinipace Worldwide and NaPro BioPharmaceutics, in addition to experience as an analytical and physical chemist. He holds a Bachelor of Science in Chemistry from the University of Miami.
Mr. Ferrigno has experience managing all aspects of finance departments, having worked at pharmaceutical company Daiichi Sankyo, the Sarah Cannon Research Institute and Clinical Trials Network of Texas. He is a CPA and holds an MBA in Corporate Finance from Fairleigh Dickinson University.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, responsibly develops and brings branded pharmaceutical products to market using groundbreaking technologies that maximize quality of life for all. We are uncompromising in our focus to become the global pharmaceutical leader committed to social, environmental, economic, and ethical responsibility. Dedicated to using our internal partnerships, we deliver the next generation of trailblazing products that are responsible by design. The Company's first product under development, ZTlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com.
ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.
© 2015 SCILEX Pharmaceuticals, Inc. All Rights Reserved.
SOURCE SCILEX Pharmaceuticals, Inc.